Amplitude Venture Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 20
Average round size
info
The average size of a deal this fund participated in
$32M
Portfolio companies 18
Rounds per year 5.00
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 5
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Artificial Intelligence

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Amplitude Venture Capital:
Typical Co-investors
Amplitude Venture Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Amplitude Venture Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Canada
Funds with similar focus located in Canada:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ASR -
BIRD Energy Israel, Tel Aviv, Tel Aviv
Blank Slate Ventures Chattanooga, Tennessee, United States
DGS -
easyJet PLC Genoa, Italy, Liguria
Echo Broadband Germany, Nordrhein-Westfalen, Siegburg
Global Philanthropic -
Guangdong Billionhome Fund Management China, Guangdong, Guangzhou
Hangzhou Dekuan Technology China, Hangzhou, Zhejiang
Huamin China, Foochow, Fujian
Huayuan Shuju China, Jingan, Shanghai
Inner Loop Capital Baltimore, Maryland, United States
Involved Investors -
Iporanga Ventures Brazil, São Paulo, Sao Paulo
LAUNCHub Ventures Bulgaria, Grad Sofiya, Sofia
Ningbo GQY -
Sansan Chiyoda, Japan
Sino-Rock Investment Management China, Hong Kong, Hong Kong Island
Techstars Los Angeles Accelerator California, Los Angeles, United States
Yeahmobi Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

DrugBank

Biotechnology
Health Care
Pharmaceutical
$7M11 Apr 2022 Edmonton, Canada

Celsius Therapeutics

Biotechnology
Emergency Medicine
Genetics
Health Care
$83M24 Mar 2022 Cambridge, Massachusetts, United States

Congruence Therapeutics

Biotechnology
Medical
$50M08 Feb 2022 Montréal, Quebec, Canada

Gandeeva Therapeutics

Biotechnology
Life Science
$40M31 Jan 2022 Vancouver, British Columbia, Canada

InVivo AI

Artificial Intelligence
Machine Learning
Pharmaceutical
Therapeutics
$7M15 Dec 2021 Montreal, Quebec, Canada

Prilenia

Biotechnology
Pharmaceutical
$43M03 Nov 2021 Boston, Massachusetts, United States

LQT Therapeutics

Biotechnology
Therapeutics
$19M10 Aug 2021 Laval, Quebec, Canada

Deep Genomics

Artificial Intelligence
Biotechnology
Genetics
Therapeutics
$180M28 Jul 2021 Old Toronto, Ontario, Canada

Giiant Pharma

Biopharma
Biotechnology
Health Care
Life Science
$11M21 May 2021 Montréal, Quebec, Canada
News
Deep Genomics Raises $180M in Series C Financing

– Deep Genomics announced the closing of a $180m Series C financing round.
– The round was led by SoftBank Vision Fund 2 and includes participation from new investors, Canadian Pension Plan Investment Board, Fidelity Management & Research Company, Alexandria Venture Investments, and existing investors Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures.
– Deep Genomics uses AI and machine learning to program and prioritize transformational RNA therapeutics for genetic diseases.
– The company has leveraged its strategic geographical advantage by combining its teams in Toronto, the birthplace of deep learning and the fastest growing technology hub in North America, with the Boston-Cambridge biotechnology hub, by hiring Jeffrey Brown, PhD, as VP of Preclinical Research, Ferdinand Massari, MD, as Chief Medical Officer, and Amanda Kay, PhD, as Chief Business Officer.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Amplitude Venture Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: